MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from maturities
and sales of...
$107,748K
Proceeds from issuance of
common stock in...
$9,750K
Proceeds from employee
stock option...
$2,676K
Proceeds from sale of
in-process research and...
$30,000K
Net cash provided by
(used in) investing...
$56,581K
Net cash provided by
financing activities
$12,255K
Canceled cashflow
$81,167K
Canceled cashflow
$171K
Net decrease in cash
and cash...
$11,464K
Canceled cashflow
$57,372K
Purchases of marketable
securities
$81,167K
Change in fair value of
cvr liability
-$72,469K
Stock-based compensation
$12,806K
Accrued and other
liabilities
$3,653K
Interest proceeds from
maturities of zero coupon...
$372K
Related party accounts
payable
$36K
Payment of deferred
offering costs in...
$171K
Net cash used in
operating activities
-$57,372K
Canceled cashflow
$89,336K
Net loss
-$69,005K
something is missing
-$42,199K
Gain on sale of
in-process research and...
$30,000K
Accounts payable
-$3,212K
Net accretion of
discount on marketable...
$2,059K
Prepaid expenses and
other assets
$233K
Back
Back
Cash Flow
source: myfinsight.com
Spyre Therapeutics, Inc. (SYRE)
Spyre Therapeutics, Inc. (SYRE)